top of page
  • mirailabbio

Intermittent administration of nicotinamide mononucleotide (NMN) by IV drip!

Tokyo Ginza Wellness & Aging Clinic (location: Chuo-ku, Tokyo; Director: Takahiro Otani)

has launched the world's first clinical study to evaluate the effects of multiple doses of nicotinamide mononucleotide (NMN) administered by IV drips every few days.

This clinic aims to "treat aging" taking different approaches, starting with the use of NMN. Recently, this clinic has established a methodology to use nicotinamide adenine dinucleotide (NAD) as a marker of aging degree and has started using it in actual medical treatments (1). NAD is a substance that decreases with age and that is probably involved in the mechanisms behind various aging phenomena.

A clinical study conducted at the University of Tokyo has revealed that the intake of NMN improves motor functions (for example, walking speed or grip strength), and tends to cause a positive impact on hearing (2). In addition, animal experiments on mice and other animals have reported that the administration of NMN reduces various aging-related conditions, such as obesity, diabetes, fatty liver, hyperlipidemia, decreased muscle metabolic capacity, decreased bone density, and decreased activity levels.

Numerous NMN studies on animals report that anti-aging effects have been observed after direct administration of NMN in the form of injections. However, most research on humans have employed oral administration, and regarding IV drips, a single dose was used for the safety tests.

In this clinical study, 20 healthy adult male and female subjects will receive several NMN IV drips every few days. Hematological and blood biochemical tests will be performed to confirm the safety of NMN IV drips. In addition, we will explore the effects of NMN IV drips through the measurement, before and after the NMN drip, of biomarkers that are related to aging, like NAD and mitochondrial level (3), and the subjective evaluation of the test participants.

The NMN used for this research will be provided by Mirailab Bioscience Inc. (HQ: Chuo-ku, Tokyo; CEO: Megumi Tanaka). Mirailab Bioscience’s NMN products are highly evaluated for their quality and have been chosen for research funded by the U.S. Department of Defense at the University of Washington, School of Medicine (4).

With this research, we hope to expand the use of NMN and further explore its possibilities, contributing to the extension of the healthy life expectancy in our super-aging society and to the future development of health care and medicine.

MORE DETAILS ON THIS CLINICAL STUDY:

FOOTNOTES

CONTACT US:

Tokyo Ginza Wellness & Aging Clinic

252 views0 comments

Comentarios


bottom of page